Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

NCT00529763 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
121
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb